FrancophonIA/ELRC3.0 huggingface dataset:
English: The amount of defibrotide excreted in urine over 24 hrs was about 5% of the total dose administered in those with renal impairment versus about 12% in healthy subjects.
Estonian: 24 tunni jooksul eritus neerukahjustusega patsientidel uriiniga defibrotiidi ligikaudu 5% manustatud koguannusest võrreldes ligikaudu 12%-ga tervetel uuringus osalejatel.
English: Defibrotide works by protecting the cells of the blood vessels and preventing or breaking down the blood clots.
Estonian: Defitelio toimib sel teel, et kaitseb veresoonte rakke ja hoiab ära verehüüvete tekke või lagundab tekkinud verehüübed.
English: Before dilution, each vial should be inspected for particles.
Estonian: Enne lahjendamist tuleb kontrollida iga viaali nähtavate osakeste esinemise suhtes.
English: Defitelio must be prescribed and administered to patients by specialised physicians experienced in the diagnosis and treatment of complications of HSCT.
Estonian: Defiteliot tohib välja kirjutada ja patsientidele manustada üksnes eriarst, kellel on kogemusi vereloome tüvirakkude siirdamise tüsistuste diagnoosimises ja ravis.
English: Talk to your doctor before using Defitelio:
Estonian: Enne Defitelio kasutamist pidage nõu oma arstiga:
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One mL of concentrate contains defibrotide* 80 mg corresponding to a quantity of 200 mg in 2.5 mL in a vial, and corresponding to a concentration in the range of 4 mg/mL to 20 mg/mL after dilution.
Estonian: Üks milliliiter kontsentraati sisaldab 80 mg defibrotiidi*, mis vastab 200 mg defibrotiidile 2,5 ml viaalis, ja pärast lahjendamist sisaldab 1 ml lahust defibrotiidi kontsentratsioonivahemikus 4 mg/ml kuni 20 mg/ml.
English: Open Label Treatment IND (25mg/kg/day)
Estonian: Uuritava ravimi avatud uuring (25 mg/kg ööpäevas)
English: Defitelio might be considered free of proarrhythmic toxicity related to QT changes.
Estonian: Defiteliol ei ole seetõttu QT intervalli muutustest tulenevat proarütmilist toksilisust.
English: Phone: +39 031 5373200 Fax: +39 031 5373241 info@gentium.it
Estonian: Telefon +39 031 537 3200 Faks +39 031 537 3241 info@gentium.it
English: Historical Control
Estonian: Varasem kontrollrühm
English: A controlled randomised prophylaxis study (Study 2004-000592-33) was conducted in the paediatric patients undergoing HSCT.
Estonian: Vereloome tüvirakkude siirdamisega lastel on läbi viidud kontrollitud randomiseeritud ennetusravi uuring (uuring 2004-000592-33).
English: Defitelio should be diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion or 5% glucose solution for infusion (see section 6.3 for concentration range and stability of the diluted solution) to a suitable concentration to permit 2 hours infusion time (see section 4.2).
Estonian: Defiteliot võib lahjendada 9 mg/ml (0,9%) naatriumkloriidi infusioonilahusega või 5% glükoosi infusioonilahusega (vt lõik 6.3 kontsentratsioonide vahemiku ja lahjendatud lahuse stabiilsuse kohta) sobiva kontsentratsioonini, mis võimaldab 2-tunnist infusiooni (vt lõik 4.2).
English: If you experience any of these side effects, you should contact your doctor immediately.
Estonian: Kui teil tekib mõni eelnimetatud kõrvaltoimetest, võtke kohe ühendust oma arstiga.
English: Common (may affect up to 1 in 10 people)
Estonian: Sageli esinevad kõrvaltoimed (võivad tekkida kuni 1 inimesel 10-st)
English: If a dose of Defitelio has been forgotten
Estonian: Kui Defitelio annus jääb vahele
English: It is not known whether defibrotide is excreted in human milk.
Estonian: Ei ole teada, kas defibrotiid eritub rinnapiima.
English: Defitelio has been used in clinical trials in patients with hepatic impairment without dose adjustment with no major safety issues identified (see section 4.2).
Estonian: Kliinilistes uuringutes on Defiteliot maksakahjustusega patsientidel annust kohandamata kasutatud, ilma et seejuures oleks täheldatud ohutusprobleeme (vt lõik 4.2)
English: Repeated intravenous administration of defibrotide, at doses below and close to the human therapeutic dose, to juvenile rats resulted in a delay in the mean age of preputial separation, suggesting a delay in the onset of male puberty in rats.
Estonian: Defibrotiidi korduv intravenoosne manustamine noortele rottidele annustes, mis olid lähedased inimesel kasutatavale terapeutilisele annusele või väiksemad, põhjustas keskmise vanuse edasilükkumist, mil leidis aset eesnaha separatsioon (eesnaha eraldumine sugutipeast).
English: Potential interactions with other medicinal products Defibrotide does not inhibit or induce CYP450s (see section 5.2).
Estonian: Defitelio ei inhibeeri ega indutseeri CYP450 ensüüme (vt lõik 5.2).
English: Each 2.5 mL vial contains 200 mg defibrotide and each mL solution contains 80 mg defibrotide.
Estonian: Üks 2,5 ml viaal sisaldab 200 mg defibrotiidi ja 1 ml lahust sisaldab 80 mg defibrotiidi.
English: In the paediatric prevention study at 25 mg/kg/day there was an increased incidence of any bleeding events in the defibrotide group compared with the treatment group.
Estonian: Ennetusravi uuringus lastel annusega 25 mg kehakaalu kg kohta ööpäevas täheldati defibrotiidirühmas ravirühmaga võrreldes suuremat verejooksude esinemissagedust.
English: It can be diluted with 5% glucose solution for infusion or sodium chloride 9 mg/mL (0.9%) solution for infusion, to a suitable concentration to permit infusion over 2 hours.
Estonian: Seda võib lahjendada 5% glükoosi infusioonilahusega või 9 mg/ml (0,9%) naatriumkloriidi infusioonilahusega sobiva kontsentratsioonini, mis võimaldab 2-tunnist infusiooni.
English: *=Kaplan Meier estimates for time-to-event analysis by Day100
Estonian: Elulemus päevaks p = 0,0341 * = Kaplan-Meieri hinnangud sündmuse tekkeni kulunud aja analüüsis päevaks +100
English: • localized blood collection out of the vessel (hematoma) in the brain
Estonian: • piirdunud verekogum ajus väljaspool veresoont (verevalum);
English: From a microbiological point of view, after dilution, the reconstituted medicinal product should be used immediately.
Estonian: Ravimi kasutusaegne stabiilsus pärast viaali esmakordset avamist ja/või lahjendamist Mikrobioloogilise saastatuse vältimiseks tuleb manustamiskõlblikuks muudetud ravim pärast lahjendamist kohe ära kasutada.
English: Defitelio 6.25 mg/kg was administered intravenously over 2 hours to subjects every 6 hours.
Estonian: Defiteliot 6,25 mg/kg manustati uuringus osalejatele iga 6 tunni jooksul intravenoosselt 2 tunni jooksul.
English: • blood in the urine
Estonian: • vere esinemine uriinis;
English: Dose adjustment is not required for patients with renal impairment or who are on intermittent haemodialysis (see section 5.2).
Estonian: Neerukahjustusega või aeg-ajalt hemodialüüsi saavatel patsientidel ei ole annuse kohandamine vajalik (vt lõik 5.2).
English: Also contains: sodium citrate dihydrate, hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections
Estonian: Abiained on: naatriumtsitraatdihüdraat, vesinikkloriidhape ja naatriumhüdroksiid (pH korrigeerimiseks), süstevesi.
English: • Data analysis from CIBMTR for patients treated and not treated with defibrotide
Estonian: International Blood and Marrow Transplant Research, CIBMTR) andmete analüüsi defibrotiidiga ravitud ja mitteravitud patsientide kohta
English: Hydrochloric acid (for pH adjustment)
Estonian: Naatriumtsitraatdihüdraat Vesinikkloriidhape (pH korrigeerimiseks) Naatriumhüdroksiid (pH korrigeerimiseks) Süstevesi
English: Individual Studies
Estonian: Üksikuuringud
English: Defitelio PK Parameters Mean ± SD
Estonian: Defitelio farmakokineetiline näitaja Keskmine ± SD
English: Dose-Finding (25mg/kg/day arm)
Estonian: Annuse leidmise uuring (25 mg/kg ööpäevas rühm)
English: A volume of the sodium chloride 9 mg/mL (0.9%) solution for infusion or glucose 5% solution for infusion from the infusion bag should be withdrawn and discarded, equal to the total volume of Defitelio solution to be added.
Estonian: 9 mg/ml (0,9%) naatriumkloriidi infusioonilahuse või 5% glükoosi infusioonilahuse infusioonikotist tuleb süstlasse tõmmata ja ära visata lahuse kogus, mis vastab infusioonikotile lisatavale Defitelio lahuse üldkogusele.
English: Consideration should be given to discontinuation of Defitelio during use of such therapy.
Estonian: Eelnimetatud ravi korral tuleb kaaluda Defitelio manustamise lõpetamist.
English: Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.
Estonian: Defitelio on näidustatud raske venooklusiivse maksahaiguse, sinusoidaalse obstruktsiooni sündroomi raviks vereloome tüvirakkude siirdamise korral.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 2.5 mL
Estonian: PAKENDI SISU KAALU, MAHU VÕI ÜHIKUTE JÄRGI
English: After the infusion is complete, the intravenous line should be flushed with sodium chloride 9 mg/mL (0.9%) solution for infusion or glucose 5% solution for infusion.
Estonian: Pärast infusiooni lõpetamist tuleb infusioonisüsteem läbi loputada 9 mg/ml (0,9%) naatriumkloriidi infusioonilahuse või 5% glükoosi infusioonilahusega.
English: Haematemesis Mouth haemorrhage
Estonian: Lööve Kihelus Petehhiad
English: How you will be given Defitelio
Estonian: Kuidas teile Defiteliot manustatakse
English: The solution is clear light yellow to brown, free from particulate matter or turbidity.
Estonian: Selge helekollane kuni pruun lahus, mis ei sisalda nähtavaid osakesi ega ole hägune.
English: Cmax (µg/mL) tmax (h)# AUCt (µg/mL*h) AUC (µg/mL*h) Vd (mL) CL (L/h) Kel (1/h) t1/2 (h)
Estonian: Eliminatsioonikonstant; Kel (1/h) Poolväärtusaeg; t1/2 (h)
English: Marketing Authorisation Holder and Manufacturer Gentium Srl
Estonian: Ravimipartii kasutamiseks vabastamise eest vastutava tootja nimi ja aadress Gentium S.r.l.
English: 4.5 Interaction with other medicinal products and other forms of interaction Potential interactions with recombinant t-PA
Estonian: 4.5 Koostoimed teiste ravimitega ja muud koostoimed
English: The combined volumes of Defitelio should be added to the sodium chloride 9 mg/mL (0.9%) solution for infusion or glucose 5% solution for infusion.
Estonian: Kokkusegatud Defitelio lahus tuleb lisada 9 mg/ml (0,9%) naatriumkloriidi infusioonilahuse või 5% glükoosi infusioonilahuse infusioonikotile.
English: Piazza XX Settembre, 2 22079 Villa Guardia (Como) Italy
Estonian: 22079 Villa Guardia (Como) Itaalia
English: Effective contraception is required for patients and partners of patients during exposure to Defitelio and for one week subsequent to discontinuation.
Estonian: Ravi ajal Defitelioga ja ühe nädala vältel pärast ravi lõpetamist peavad patsiendid ja nende partnerid kasutama tõhusat rasestumisvastast meetodit.
English: Very Common (may affect more than 1 in 10 people )
Estonian: Väga sage (võib tekkida rohkem kui 1 inimesel 10-st) • madal vererõhk
English: Gastrointestinal haemorrhage Vomiting
Estonian: Seedetrakti verejooks Oksendamine Kõhulahtisus Iiveldus
English: It is used to treat a condition called hepatic veno-occlusive disease, in which the blood vessels in the liver become damaged and obstructed by blood clots.
Estonian: See on haigus, mille korral tekib maksa veresoonte kahjustus ja need ummistuvad verehüüvetega.
English: − If you get any side effects, talk to your doctor.
Estonian: - Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arstiga.
English: No special precautions are indicated.
Estonian: Muid ettevaatusabinõusid ei ole laste puhul vaja kasutada.
English: A significantly higher proportion of patients in the Defitelio treated group achieved a complete response defined as total bilirubin less than 2 mg/dL and resolution of MOF (multiple organ failure); Day+100 complete response was 23.5% (24/102) with Defitelio versus 9.4% (3/32) in the historical control (p=0.013).
Estonian: Päeva +100 täielik ravivastus saavutati 23,5%-l Defitelioga ravitud patsientidest (24/102) võrrelduna 9,4%-ga (3/32) varasema kontrollrühma patsientidest (p = 0,013).
English: Temporary discontinuation of Defitelio is recommended in patients who undergo surgery or invasive procedures at significant risk of major bleeding.
Estonian: Patsientidel, kellel on plaanis operatsioon või invasiivne protseduur, millega kaasneb oluline verejooksu risk, on soovitatav Defitelio manustamine ajutiselt katkestada.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenicity.
Estonian: Farmakoloogilise ohutuse, korduvtoksilisuse, genotoksilisuse ja kartsinogeensuse mittekliinilised uuringud ei ole näidanud kahjulikku toimet inimesele.
English: Haemorrhage
Estonian: Ajuverevalum
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not normally be expected to exceed 24 hours at 2-8°C.
Estonian: Kui ravimit ei kasutata kohe, vastutab selle säilitamisaja ja -tingimuste eest kasutaja.
English: Conjunctival haemorrhage
Estonian: Sidekesta verejooks
English: NAME OF THE MEDICINAL PRODUCT Defitelio 80 mg/mL concentrate for solution for infusion
Estonian: RAVIMPREPARAADI NIMETUS Defitelio 80 mg/ml infusioonilahuse kontsentraat
English: In a mouse model of thromboembolism, recombinant t-PA potentiated the antithrombotic effect of defibrotide when given intravenously and thus co-administration may present an increased risk of haemorrhage and is contraindicated (see section 4.3).
Estonian: Trombemboolia hiire mudelis tugevdas rekombinantne t-PA intravenoosselt manustatud defibrotiidi tromboosivastast toimet, seetõttu võib nende samaaegsel manustamisel olla suurem verejooksu tekke risk.
English: Defitelio 80 mg/mL concentrate for solution for infusion defibrotide
Estonian: Defitelio 80 mg/ml infusioonilahuse kontsentraat Defibrotiid
English: Possible side effects.
Estonian: Võimalikud koostoimed teiste ravimitega
English: − Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 − Concomitant use of thrombolytic therapy (e.g. t-PA) (see section 4.5).
Estonian: - Samaaegne trombolüütiline ravi (nt t-PA) (vt lõik 4.5).
English: NAME OF THE MEDICINAL PRODUCT Defitelio 80 mg/mL concentrate for solution for infusion defibrotide
Estonian: RAVIMPREPARAADI NIMETUS Defitelio 80 mg/ml infusioonilahuse kontsentraat Defibrotiid
English: What Defitelio looks like and contents of the pack Defitelio is a clear light yellow to brown concentrate for solution for infusion, free from particulate matter or turbidity.
Estonian: Defitelio on helekollane kuni pruun infusioonilahuse kontsentraat, mis ei sisalda nähtavaid osakesi ega ole hägune.
English: • nausea
Estonian: • sügelus
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Defitelio 80 mg/mL sterile concentrate defibrotide
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Defitelio 80 mg/ml infusioonilahuse kontsentraat Defibrotiid i.v.
English: Six patients with an estimated glomerular filtration rate <30 mL/min/1.73m2 (calculated using the Modification of Diet in Renal Disease equation) and not currently on dialysis were compared to 6 healthy subjects with similar baseline demographics.
Estonian: (arvutatud neeruhaiguse korral dieedi muutmise valemit kasutades), kes ei saanud sel ajal dialüüsi, võrreldi 6 terve uuringus osalejaga, kellel olid sarnased ravieelsed demograafilised andmed.
English: • blood in the stool
Estonian: • verejooks süstekohast;
English: Valeant Pharma Magyarország Kft. Tel: +36-1-345-5900
Estonian: Tel: +36-1-345-5900
English: Metabolism
Estonian: Hemotooraks
English: Cerebral haemorrhage
Estonian: Veriokse Suuverejooks
English: P: +39 031 5373200 F: +39 031 5373241 info@gentium.it
Estonian: Gentium Srl Piazza XX Settembre 2 Villa Guardia 22079 Itaalia T +39 031 537 3200 F +39 031 537 3241 info@gentium.it
English: Alive at Day +100 VOD resolved by Day +100
Estonian: Venooklusiivne haigus paranenud päeval +100
English: 19 May 2010
Estonian: 19. mai 2010
English: What is Beprana?
Estonian: Mis on Beprana?
English: The main measure of effectiveness was based on how patients rated their pain and disease activity after 13 weeks of treatment.
Estonian: Efektiivsuse põhinäitaja oli see, kuidas patsiendid hindasid valu ja haiguse aktiivsust pärast 13-nädalast ravi.
English: Withdrawal of the marketing authorisation application for Beprana (naproxcinod) EMA/364651/2011
Estonian: Müügiloa taotluse tagasivõtmise teave: Beprana (naprokstsinood) EMA/364651/2011
English: The Committee had concerns about its effect on blood pressure and the potential risk of toxic effects in the liver.
Estonian: Komitee oli mures ravimi mõju pärast vererõhule ja maksale avalduvate võimalike toksiliste mõjude riski pärast.
English: Two of the studies involved 1,929 patients with knee osteoarthritis while the third study involved 810 patients with hip osteoarthritis.
Estonian: Kahes uuringus osales 1929 põlve osteoartriidiga patsienti ning kolmandas uuringus 810 puusa osteoartriidiga patsienti.
English: It was to be available as capsules.
Estonian: Seda kavatseti turustada kapslitena.
English: Beprana is a medicine that contains the active substance naproxcinod.
Estonian: Beprana on ravim, mis sisaldab toimeainena naprokstsinoodi.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Beprani kliinilistes uuringutes osalevaid patsiente.
English: Withdrawal of the marketing authorisation application for Beprana (naproxcinod)
Estonian: Müügiloa taotluse tagasivõtmise teave: Beprana (naprokstsinood)
English: Three main studies in patients were carried out, comparing Beprana with naproxen (another medicine used in osteoarthritis) and placebo (a dummy treatment).
Estonian: Patisentidel teostati kolm põhiuuringut, milles võrreldi Bepranat naprokseeniga (samuti osteoartriidi puhul kasutatav ravim) ja platseeboga (näiv ravim).
English: It is expected to counterbalance the effect of Naproxen of increasing blood pressure.
Estonian: See peaks olema vastukaaluks naprokseeni vererõhku tõstvale toimele.
English: How is Beprana expected to work?
Estonian: Milline on Beprana eeldatav toime?
English: The active substance in Beprana, naproxcinod, is converted in the body into the drug naproxen and a chemical that releases nitric oxide.
Estonian: Beprana toimeaine naprokstsinood muudetakse organismis naprokseeniks ja lämmastikoksiidi vabastavaks kemikaaliks.
English: It works by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation process.
Estonian: See blokeerib ensüümi (tsüklooksügenaas), mis toodab põletikuprotsessis osalevaid aineid prostaglandiine.
English: The CHMP noted that while there was evidence showing that Beprana was effective in relieving the signs and symptoms of osteoarthritis of the knee and hip, its benefits were not sufficient to outweigh the identified risks.
Estonian: Inimravimite komitee märkis, et kuigi tõendid näitasid, et Beprana oli põlve ja puusa osteoartriidi nähtude ja sümptomite leevendamisel efektiivne, ei ole selle kasulikkus suurem kui sellega kaasnevad riskid.
English: On 19 April 2011, NicOx S. A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Beprana in adults for the relief of signs and symptoms of osteoarthritis of the knee and hip.
Estonian: NicOx S. A. teatas 19. aprillil 2011 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Beprana müügiloa taotlus.
English: By reducing the production of prostaglandins, Beprana is expected to reduce the inflammation and pain seen in osteoarthritis.
Estonian: Prostaglandiinide tekke vähendamisega peaks Beprana leevendama osteoartriidi puhul esinevat põletikku ja valu.
English: Nitric oxide is a vasodilator, a substance that causes the widening of blood vessels.
Estonian: Lämmastikoksiid on vasolidaator ehk veresoonte laienemist põhjustav aine.
English: Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Beprana could not have been approved for the relief of signs and symptoms of osteoarthritis of the knee and hip.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Beprana kasutamist põlve ja puusa osteoartriidi nähtude ja sümptomite leevendamiseks ei ole võimalik heaks kiita.
English: The effects of Beprana were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Beprana toimet muude katsetega.
English: Beprana was expected to be used to relieve the signs and symptoms of osteoarthritis (swelling and pain in the joints) of the knee and hip in adults.
Estonian: Bepranat kavatseti kasutada põlve ja puusa osteoartriidi nähtude ja sümptomite (liigeste tursed ja valu) leevendamiseks täiskasvanutel.
English: What was Beprana expected to be used for?
Estonian: Milleks kavatseti Bepranat kasutada?
English: It is available as capsules (1.5, 3, 4.5 and 6 mg).
Estonian: Seda turustatakse kapslitena (1,5, 3, 4,5 ja 6 mg).
English: EMEA/H/C/002036
Estonian: EMA/383424/2015 EMEA/H/C/002036
English: Rivastigmine Actavis should be given twice a day, with morning and evening meals.
Estonian: Rivastigmine Actavist manustatakse kaks korda ööpäevas, hommiku- ja õhtusöögi ajal.
English: The full EPAR for Rivastigmine Actavis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rivastigmine Actavise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine Actavis on 16 June 2011.
Estonian: Euroopa Komisjon andis Rivastigmine Actavise müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. juunil 2011.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom mitte sagedamini kui kahenädalase intervalliga tavapärase annuseni 3-6 mg kaks korda ööpäevas.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine Actavis by the patient.
Estonian: Ravi tohib alustada vaid juhul, kui on olemas hooldaja, kes jälgib regulaarselt, kuidas patsient kasutab Rivastigmine Actavist.
English: The Committee recommended that Rivastigmine Actavis be given marketing authorisation.
Estonian: Komitee soovitas anda Rivastigmine Actavise müügiloa.
English: Rivastigmine Actavis rivastigmine
Estonian: Rivastigmine Actavis rivastigmiin
English: Rivastigmine Actavis is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Estonian: Rivastigmine Actavist kasutatakse kerge kuni mõõdukalt raske Alzheimeri dementsusega patsientide raviks; see on progresseeruv ajuhäire, mis kahjustab järk-järgult mälu, vaimseid võimeid ja käitumist.
English: It can also be used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Estonian: Ravimit kasutatakse ka kerge kuni mõõdukalt raske dementsuse raviks Parkinsoni tõvega patsientidel.
English: For more information about treatment with Rivastigmine Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rivastigmine Actavisega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.